Valvular & structural heart diseaseCohort study
Outcomes of patients with large anatomies undergoing transcatheter tricuspid valve replacement with the LuX-Valve Plus system
- European TRINITY study cohort
Authors' conclusion
TTVR with the LuX-Valve Plus system to treat patients with severe or greater symptomatic TR and a large tricuspid annulus was associated with high intraprocedural and 30-day clinical success rates, significant TR reduction and functional improvement, and low permanent pacemaker implantation rates.
Study context
- Population
- Patients with severe or greater symptomatic tricuspid regurgitation (TR) and large tricuspid annuli undergoing transcatheter tricuspid valve replacement (TTVR) with the 55–70 mm LuX-Valve Plus system
- Participants
- 114 enrolled patients
- Outcome
- Co-primary endpoints: intraprocedural and 30-day clinical success (Tricuspid Valve Academic Research Consortium criteria)
- Follow-up
- Intraprocedural and 30 days
Main finding
As reported in the abstract
Intraprocedural success
95.6%
Thirty-day clinical success
91.2%
Observational data: associations, not effects.
Further findings
Residual TR moderate or less
- Patients with residual TR moderate or less
- 93.7%
Kansas City Cardiomyopathy Questionnaire score
- Mean score improved from
- 57.3±20.7 points
- Mean score improved to
- 71.0±23.5 points
- p<0.001
New York Heart Association Class III-IV symptoms · 30 days
- Baseline
- 57.1%
- 30 days
- 20.9%
- p<0.001
Safety
| Outcome | Values |
|---|---|
| Cardiac surgery within the first 24 hours | LuX-Valve Plus 1.8% |
| Pacemaker implantation · 30 days | LuX-Valve Plus 6.1% |
Intraprocedural mortality or stroke
- No cases of intraprocedural mortality or stroke
Original publication
Outcomes of patients with large anatomies undergoing transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention. Published 17 August 2026. doi:10.4244/eij-d-26-00062
Summarised from the published abstract; every number is checked against it